Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Research & Development (2016 - 2025)

Fate Therapeutics' Research & Development history spans 14 years, with the latest figure at $25.4 million for Q4 2025.

  • For Q4 2025, Research & Development fell 24.35% year-over-year to $25.4 million; the TTM value through Dec 2025 reached $107.8 million, down 20.13%, while the annual FY2025 figure was $107.8 million, 20.13% down from the prior year.
  • Research & Development reached $25.4 million in Q4 2025 per FATE's latest filing, down from $25.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $87.2 million in Q4 2022 to a low of $25.4 million in Q4 2025.
  • Average Research & Development over 5 years is $47.6 million, with a median of $37.8 million recorded in 2023.
  • Peak YoY movement for Research & Development: surged 80.07% in 2021, then tumbled 63.51% in 2023.
  • A 5-year view of Research & Development shows it stood at $69.5 million in 2021, then grew by 25.43% to $87.2 million in 2022, then crashed by 63.51% to $31.8 million in 2023, then grew by 5.64% to $33.6 million in 2024, then fell by 24.35% to $25.4 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Research & Development are $25.4 million (Q4 2025), $25.8 million (Q3 2025), and $27.4 million (Q2 2025).